API Holdings (Pharmeasy) Unlisted Shares
PharmEasy Plans To Raise INR 3,500 Cr Through Right Issue
Inc42
2 min read
Health-tech unicorn PharmEasy, founded in 2015, plans to raise 3500 Cr through Right Issue next week to repay a large portion of its debt to Goldman Sachs.
Justification
The startup has so far raised more than $1.5 Bn across multiple rounds.
Received funding commitment worth INR 2000 Cr from Temasek Holdings, CDPQ, LGT, and Abu Dhabi sovereign wealth fund ADQ, among others.
Likely to receive 1200 Cr funding from Manipal Health Enterprises founder Ranjan Pai’s family office.
The company took high-cost debt from Goldman to buy ThyroCare, but broke a debt covenant stating to raise 1000 Cr through equity, but failed to do so.
Despite revenue growth to INR 5,729 Cr, losses surged to INR 2,731 Cr in FY22 of the company.
Although the company is facing financial difficulties, the infusion of capital through the right issue & other funding methods will uplift the company.
The funds raised along with repaying debt might also be used for expanding the business operations of the company.
Precize Daily Pulse
The latest news in the world of Unlisted Shares, summarised by our experts.
Company
Our Office
Office No. 1219, The Summit Business Park, Andheri Kurla Road, Andheri East, Mumbai, Maharashtra - 400093
Find us on Googlesupport@precize.in
+91 7738336457
All trademarks and logos or registered trademarks and logos found on this Site or mentioned herein belong to their respective owners and are solely used for informational and educational purposes.
The material presented in this advertisement is for informational purposes only and should not be construed as investment advice or investment availability. It is not a recommendation of, or an offer to sell or solicitation of an offer to buy, any particular unlisted share, security, strategy, or investment product. Investing in the private market and securities involves risks, including the potential loss of money, and past performance does not guarantee future results. Market trends, data interpretations, graph projections are provided for informational and illustrative purposes and may not reflect actual future performance. Nothing on this website should be construed as personalized investment advice or should not be treated as legal, financial, or any other form of advice. Precize is not liable for financial or any other form of loss incurred by the user or any affiliated party based on information provided herein.
Precize is neither a stock exchange nor does it intend to get recognized as a stock exchange under the Securities Contracts Regulation Act, 1956. Precize is not authorized by the capital markets regulator to solicit investments. The securities traded on these platforms are not traded on any regulated exchange.
The website will be updated regularly.
Copyright © 2026 - Precize - All Rights Reserved